ArThec
Bridging clinical cell therapy and global manufacturing
- Biotechnology (tissue-engineered ATMP)
- Gdańsk, Poland
- February 2026
A4BEE prepared this analysis from publicly available sources. It reflects our own reading of ArThec's published strategy and is not endorsed by, or produced in cooperation with, ArThec. Company website
Strategic priorities
ArThec is a Polish biotechnology company developing PEARL, a tissue-engineered autologous cartilage implant built around in-vitro cell cultivation. The European Medicines Agency classified PEARL as a tissue-engineered Advanced Therapy Medicinal Product in May 2021, which places it under EudraLex Volume 4 Part IV — the most stringent data-integrity regime in pharmaceutical regulation. The company is positioning for a 2026/2027 commercial launch aimed at a global osteoarthritis population estimated at 177 million individuals.
Operations are anchored at a single R&D and pilot manufacturing site in Gdańsk, with a published ambition to run the same PEARL procedure at any suitably certified GMP facility in the world — what ArThec calls Redistributed Manufacturing. That ambition depends on standardising equipment interfaces, audit trails and quality evidence across sites the company does not yet operate, which is a digital architecture question before it is a logistics question.
The product is autologous: every batch is a single patient donation that cannot be re-made if the run fails. Continuous monitoring of bioreactor conditions, real-time KPI calculation and high-availability lab computing all serve the same end — making sure the run that is happening is the run the clinical record describes. This is what the leadership's repeated reference to data being readable "from the moment a cell is harvested to the moment the hyaline cartilage is implanted" actually requires.
ArThec sits inside the Polish deep-tech funding wave that placed PLN 3.37 billion (approximately EUR 780 million) into Polish startups in 2025, against an endoprosthesis market projected to reach USD 29.79 billion by 2027 that the company is positioning to disrupt. The capital profile is consistent with a clinical-stage ATMP preparing for commercial scale-out, and the digital priorities below match that posture.
-
01
Digital lab across the therapeutic lifecycle
Connecting every data point from the surgical harvest through cultivation, quality control and implantation into a single readable record, so the therapeutic lifecycle has one history rather than several.
-
02
Manufacturing in any certified GMP facility
Running the PEARL procedure at any suitably certified GMP site in the world on a single standard, instead of building a different version of the process at each location.
-
03
EMA and FDA evidence generation
Producing the GxP-compliant audit trail and Contamination Control Strategy evidence that EMA and FDA reviewers expect, across a network of GMP sites and across the patient-specific batch format.
-
04
Carbon-neutral growth under EU ESG rules
Operating energy-intensive Grade A cleanrooms within EU ESG expectations, supported by IoT-based energy monitoring and AI-driven optimisation of cleanroom HVAC load.
Challenges we see
- Operations Manufacturing
Continuous visibility into batch-of-one cultivation
Each PEARL batch is autologous: cells from a single patient are cultivated in bioreactors over a multi-day cycle. Continuous cultivation cycles rely on trained operators for visual checks of cell growth, foam formation and contamination indicators, and a missed signal in that window ends the run.
When each batch serves one patient and cannot be repeated, the practical expectation shifts from confirming quality after the run to reading the bioreactor while it is still running.
- Digital Integration
Putting biological KPIs and live process trends in one view
Critical biological KPIs such as Viable Cell Density, Growth Rate and trophic factor concentrations are recorded in Excel or in legacy SCADA systems, separate from the live process signals the instruments generate. A company co-founder has framed the company's data need as total transparency from harvest to implantation.
Where biological metrics reach the team days after the run, the window for in-process intervention has already closed; making KPI calculations part of the same data stream as the process signals is what turns a retrospective record into a live one.
- Operations Manufacturing
Linking legacy lab instruments into one production record
ArThec's pilot line integrates instruments from multiple vendors, including Beckman Coulter and Roche, around bench-scale bioreactors. Each instrument ships its own data format, and standalone industrial PCs hold much of the supervisory software.
Where each vendor's data format ends at the instrument, the production record is reconstructed from many separate exports, and a single failed IPC can pause a run that is supposed to be continuous.
- Compliance Regulatory
Producing GxP evidence across a distributed manufacturing network
As a tissue-engineered ATMP, ArThec operates under EudraLex Volume 4 Part IV and EMA/CAT oversight, with FDA submission also planned. Every manufacturing modification must be logged in a GxP-compliant audit trail, and the Contamination Control Strategy must be demonstrable in real time.
Documentation volume scales with the number of GMP sites and the number of patient batches, so the time to assemble evidence rather than the technical content of the work increasingly determines how quickly a change or release can move.
- Digital Security
Protecting IP and patient data across dispersed GMP sites
The Redistributed Manufacturing model implies cloud-based monitoring of GMP sites ArThec does not directly operate, carrying proprietary tissue-engineering methods and patient-derived material data. The shift from passive firewalls to active anomaly detection is a stated digital need.
When monitoring has to cross site boundaries, identity-based access and continuous anomaly detection become the controls that let remote operations happen at all, rather than features added later.
Opportunities, by urgency and business impact
Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.
-
Reading bioreactor conditions with computer vision during the run
Cell growth, foam formation and contamination indicators in the cultivation cycle are visually inspected by trained operators, with reaction times set by shift presence and subjective assessment.
Camera-based monitoring of the bioreactor, with foam detection, cell morphology analytics and contamination signatures running as a continuous second observer, lets the cultivation cycle be characterised while the batch is still on the line.
- ArThec company site, https://www.arthec.eu/
- ArThec_DeepResearch.md, Operational Friction section
-
Calculating biological KPIs in real time, alongside the process signals
Viable Cell Density, Growth Rate and other biological metrics are tracked in Excel or in legacy SCADA, separate from the live process stream, so the team sees results days after the experiment ends.
An automated KPI engine that reads directly from the process data stream and exposes the values in P&ID-based dashboards, with Golden Batch overlays, makes the same numbers readable during the run instead of after it.
- ArThec_DeepResearch.md, Digital Friction section
- Company co-founder commentary on transparency from harvest to implantation
-
Removing single points of failure from the cultivation control loop
The pilot line runs supervisory software on standalone industrial PCs; a hardware failure on one of them can stop data collection during a continuous cultivation cycle.
Moving supervisory workloads onto a clustered container environment with N+1 redundancy, where workload migrates between nodes on failure, keeps monitoring continuous through a single-node loss.
- ArThec_DeepResearch.md, Legacy Equipment Failures
- ArThec Friction Analysis, Single Points of Failure
-
Building one standard for equipment integration across GMP sites
The Redistributed Manufacturing model requires running the PEARL procedure at any suitably certified GMP facility, but no single equipment-integration standard is in place across the planned network.
Implementing MTP (Module Type Package) and OPC UA as the equipment-integration baseline means a new GMP site is onboarded against the same interface and validation package, instead of against a new bespoke project.
- ArThec_DeepResearch.md, Modular Standards friction
- ArThec Investor materials, Location-Independent Manufacturing pillar
-
Securing remote operations against IP and patient data exposure
Cloud-based monitoring of distributed GMP sites increases exposure of proprietary tissue-engineering methods and patient-derived material data, with passive firewalls providing perimeter-only protection.
An identity-based access model for industrial automation, with active anomaly detection on the OT network and secure connectivity for air-gapped legacy instruments, lets remote operations happen within an auditable security envelope.
- ArThec_DeepResearch.md, Cybersecurity Vulnerabilities
- ArThec Friction Analysis, Cybersecurity for distributed manufacturing
What we'd propose
- Digital Lab
Computer vision monitoring of cultivation bioreactors
Camera-based monitoring of the cultivation bioreactor, with foam detection, cell morphology analytics and contamination signatures running as a continuous second observer, so the cultivation cycle is characterised while the batch is still running.
-
Camera-based foam detection
External cameras with OpenCV-based image processing detect foam levels in real time, distinguishing slow-rising from flash foam so the operator or the control system can act on the right kind of event.
-
Adaptive antifoam dosing
A dosing controller running interval, vector or PWM modes adjusts antifoam addition against the visual foam signal, so dosing follows the current state of the bioreactor instead of a fixed schedule.
-
Cell morphology analytics
Machine learning models trained on microscope and in-line images flag contamination signatures and cell health indicators before they are visible in offline samples, giving the cultivation team a lead on what offline assays will confirm.
- The bioreactor is observed through every hour of the run, regardless of who is on shift.
- Foam events trigger a dosing response in minutes, not at the next scheduled reading.
- Contamination signals surface earlier in the run, shortening the time between detection and action.
-
- Digital Lab
Real-time KPI engine and P&ID-based dashboards
An automated KPI engine that reads directly from the process data stream and exposes the values in dashboards laid out like the physical bioreactor, with Golden Batch overlays so the current run is compared against the best historical profile.
-
P&ID-based dashboard layouts
Dashboards built in Grafana to match the bioreactor's piping and instrumentation diagrams, reducing the cognitive distance between the screen and the equipment and shortening the path from observation to action.
-
Automated KPI calculation
Twelve or more biological KPIs, including Viable Cell Density, Viable Cell Volume, Growth Rate and CSPR, calculated inside the data platform directly from the instrument stream, so the numbers exist in the system rather than in a spreadsheet.
-
Golden Batch overlay
Overlay of the current cultivation profile against historical best runs, so deviations show up as a shape on the chart instead of as a number out of context.
- Bio-KPIs arrive in the same view as the live process signals they describe.
- Scientist self-service replaces the IT ticket that used to gate every dashboard change.
- Deviations against the Golden Batch are visible as a curve, not after a meeting.
-
- Digital CDMO
MTP-based equipment standard for distributed GMP sites
A Module Type Package (MTP) and OPC UA equipment-integration baseline, with a NAMUR-compliant PLC library, that lets a new GMP site be onboarded against the same interface and validation package as the Gdańsk pilot.
-
MTP library implementation
A PLC library compliant with VDI/VDE/NAMUR 2658, with object-oriented method modules, so a new skid is programmed against the same building blocks rather than from a blank project.
-
OPC UA backbone
OPC UA as the communication backbone between instruments, line supervision and the central data platform, with secure machine-to-machine communication and a documented information model.
-
Plug-and-produce validation pack
Pre-validated processing components and an integration guide that let any suitably certified GMP facility onboard the PEARL procedure against the same baseline, reducing the validation effort that has historically been per site.
- The same equipment standard is reusable as new GMP sites join the network.
- Vendor lock-in is reduced because the integration interface is the published standard, not a specific controller.
- Onboarding a new site moves from a one-off project to a documented procedure.
-
- Enterprise AI
Zero Trust OT security for cloud-monitored GMP operations
An identity-based access model for industrial automation, with active anomaly detection on the OT network and secure connectivity for air-gapped legacy instruments, so remote monitoring of distributed GMP sites happens inside an auditable security envelope.
-
Identity-based access control
Replace perimeter-only controls with identity verification at every access to the OT network, preventing lateral movement from a compromised credential into the manufacturing control plane.
-
Active anomaly detection on OT
Continuous monitoring that separates a sensor glitch from an attack on the controller, so the operations team is not chasing false positives while a real intrusion goes unflagged.
-
Secure air-gap bridging
A secure connectivity framework that brings data from air-gapped legacy lab instruments into the central data lake without exposing proprietary methods or patient-derived material to the public network.
- Remote monitoring of GMP sites happens inside a security envelope that has been designed for it.
- Operational technology events are classified by cause, not just by alarm.
- Legacy instruments contribute their data to the platform without joining the open network.
-
- Agents
AI agents for ATMP regulatory and quality documentation
Narrow, reviewable agents that take the recurring part of EMA/FDA documentation work: drafting deviation and change-control summaries from source records, checking a document against its template before review, and finding every controlled document a standards change affects. A named person approves every output.
-
Drafting from source records
Generate first drafts of deviation, change-control and periodic-review documents from the underlying system records, so the author edits and judges rather than assembles the document from scratch.
-
Template and completeness checking
Check a submitted document against its EMA/FDA template and the site's own checklist, returning missing or inconsistent sections before the document enters the human review queue.
-
Change impact search across the document set
When a standard, method or specification changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.
- Review queues move faster because documents arrive complete and traceable to their source records.
- The scope of a standards change is established by search, not by memory.
- Every agent output is reviewed and signed off by a named reviewer before it becomes a controlled document.
-
Where QB Systems fits
Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.
- ArThec runs cell cultivation bioreactors at pilot scale in Gdańsk and is targeting a multi-site GMP network, which matches qb-control and qb-modules for bioprocess at pilot scale.
- The current pilot line integrates legacy instruments from Beckman Coulter and Roche on standalone industrial PCs; retrofitting those instruments onto a qb control layer is a stated operational priority.
- Benchtop-to-pilot scale is the operating regime today; production scale is not in scope and remains roadmap.
-
QB Control
Software-defined bioprocess control — the hardware setup is described in software, so one platform runs different vessels and processes.
-
QB Modules
Modular hardware: edge controller, peristaltic pumps, multisensor, pressure sensor, multiscale and light — combined per process.
- Applications
- Bioreactors
Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.
- Deployment
- Retrofit
Existing equipment keeps running; QB takes over the PLC, or reads from it without touching control.
- Scale
- Pilot (50–300 L)
Stainless steel, where QB supplies the control software and integration and a certified partner builds the installation.
Digital maturity: today and target
Scored out of 100 across six dimensions. The target is what ArThec's own published ambition implies — not a perfect score.
- Data Integration 30 → 85
- Clinical Hospital Exemption data and GMP manufacturing data live in separate systems, with biological KPIs tracked in Excel. A unified platform with automated pipelines and KPI calculation is the direction of travel.
- Process Automation 25 → 80
- Visual checks of cell growth and contamination are performed by trained personnel during continuous cultivation cycles. Computer vision and closed-loop control are on the published roadmap.
- Infrastructure Resilience 35 → 90
- Standalone industrial PCs hold supervisory software for the cultivation line. High-availability clustering with N+1 redundancy is the published direction.
- Regulatory Compliance 45 → 95
- EudraLex Volume 4 Part IV and EMA/CAT oversight apply. Paper-based records and non-validated digital systems remain in use; GxP-compliant electronic audit trails and automated Contamination Control Strategy monitoring are the target.
- Modular Standards 20 → 75
- No single equipment-integration standard is in place across the planned GMP network. MTP and OPC UA adoption is what makes the Redistributed Manufacturing model practically operable.
- Cybersecurity 30 → 85
- Passive firewalls protect a perimeter that the cloud-monitored GMP network has already moved past. Identity-based access and active OT anomaly detection are the stated direction.
Check this yourself
Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.
-
Self-assessment
Find Your LIMS
Answer a few questions about your lab and get a shortlist of LIMS that fit it.
-
Self-assessment
Electronic Batch Record (eBR) Readiness
Check how far your batch records are from paperless, and what the next step is.
-
Market comparison
Digital Lab: Equipment & Integration Map
Which lab instruments connect to which systems, and where the gaps usually are.
-
Market comparison
European CDMOs Compared
The 2026 landscape: who does what, at what scale.
Think we've read this right?
Talk to usRelated reading
-
Vision systems and foam detection
Machine vision systems enhance industrial safety and quality by detecting defects and foam in real time for efficient, automated processes.
-
Accelerating lab and manufacturing operations with MTP – a modular approach
Among the various modular and plug-n-produce approaches, the Modular Type Package (MTP) approach has emerged as a game-changer.
-
Zero Trust Security Principles
The drive to find new resources for innovation and process improvement in life science companies is becoming more based on technologies.
-
Cybersecurity for industrial automation and control systems in Life Sciences
Pharma specific hardware and software development is far more complex than only Cybersecurity, but securely designed Product may address...
-
From Paper to Performance: Operational Efficiency and Compliance in Labs
Transform your QC lab with scalable digital solutions that embed compliance, boost efficiency, and deliver a future-ready competitive edge.
This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with ArThec, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].